Related Experiment Videos
[Visual field changes secondary to vigabatrin treatment].
J A Mauri-Llerda1, C Iñiguez, C Tejero-Juste
1Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. jamauri@retemail.es
Revista De Neurologia
|February 24, 2001
Summary
Long-term vigabatrin treatment for epilepsy is linked to a high prevalence of visual field defects. Early detection through serial campimetry is crucial, as clinical signs often appear late.
Area of Science:
- Neuro-ophthalmology
- Epileptology
- Pharmacovigilance
Background:
- Vigabatrin is an effective antiepileptic drug (AED) used for partial seizures.
- It functions by irreversibly inhibiting GABA-transaminase, increasing GABA levels.
- Recent reports indicate potential visual field alterations in patients on vigabatrin therapy.
Observation:
- This study investigated the prevalence and characteristics of visual field changes in adult epilepsy patients on long-term vigabatrin.
- Ophthalmological examinations included visual field testing (campimetry), funduscopy, visual evoked potentials (VEPs), and electroretinography (ERG).
Findings:
- 60% of patients (6 out of 10) exhibited campimetric alterations, with 20% showing severe defects.
- Optic nerve pallor was observed in 20% of patients.
- ERG abnormalities correlated with severe field defects; VEPs remained normal in all cases.
Implications:
- Long-term vigabatrin use is associated with a high incidence of visual field defects.
- Ophthalmological signs may not be apparent until advanced stages of visual field loss.
- Regular campimetric monitoring is essential for early detection and management of vigabatrin-induced visual field alterations.